Last Price$190.61.0%
Market Cap$10.4B
P/EBITDA LTM
42.1x
5Y avg
35.5x
Medical - Instruments & Supplies industry
median
(0.1x)
Stock quality & Intrinsic value
5/10
(0.3%) overvalued
Masimo Corporation P/EBITDA LTM
Annual
Quarterly
Daily
Crunching data... Almost there!
| Dec'07 | Jan'09 | Dec'09 | Dec'10 | Dec'11 | Dec'12 | Dec'13 | Jan'15 | Dec'15 | Dec'16 | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| P/EBITDA LTM | 11.0x | 23.4x | 22.6x | 21.5x | 12.3x | 13.4x | 16.3x | 14.5x | 16.0x | 23.4x | 9.4x | 23.7x | 35.7x | 52.2x | 54.0x | 25.0x | 21.2x |
Overvalued or undervalued?
Check the intrinsic value for MASI
and see if it's the right time to invest.
Masimo Corporation (MASI) P/EBITDA LTM comparison analysis
General
LTM P/EBITDA LTM
OTHER METRICS
Company name
Revenue growth
EPS growth
Net Income margin
Masimo CorporationMASI
(51.4x)
0.6%
(42.5%)
4.0%
Median Peer Set
19.9x
3.4%
23.0%
10.4%
Repligen CorporationRGEN
102.9x
(21.1%)
(80.9%)
5.6%
Intuitive Surgical, Inc.ISRG
75.1x
17.2%
27.7%
27.8%
Alcon Inc.ALC
22.9x
8.5%
182.9%
10.3%
West Pharmaceutical Services, Inc.WST
22.9x
(1.9%)
(15.5%)
17.0%
ResMed Inc.RMD
20.9x
10.9%
13.4%
21.8%
Baxter International Inc.BAX
18.8x
(69.5%)
(100.0%)
(6.9%)
The Cooper Companies, Inc.COO
18.4x
8.4%
32.2%
10.1%
Becton, Dickinson and CompanyBDX
18.0x
4.2%
18.3%
8.4%
AptarGroup, Inc.ATR
12.9x
2.7%
30.2%
10.5%
Hologic, Inc.HOLX
12.0x
(0.0%)
81.1%
19.6%
MASI key stats
USD
Millions
Billions
Annual
Quarterly
Trailing
Key stats
Income statement
Balance sheet
Cash Flow Statement
Valuation
Ratios
Per share
Per employee
Dividends & Yields
| Dec'04 | Dec'05 | Dec'06 | Dec'07 | Jan'09 | Jan'10 | Jan'11 | Dec'11 | Dec'12 | Dec'13 | Jan'15 | Jan'16 | Dec'16 | Dec'17 | Dec'18 | Dec'19 | Jan'21 | Jan'22 | Dec'22 | Dec'23 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
% growth | 69.4 0.0% | 107.9 55.6% | 224.3 107.9% | 256.3 14.2% | 307.1 19.8% | 349.1 13.7% | 405.4 16.1% | 439.0 8.3% | 493.2 12.4% | 547.2 11.0% | 586.6 7.2% | 630.1 7.4% | 694.6 10.2% | 798.1 14.9% | 858.3 7.5% | 937.8 9.3% | 1,143.7 22.0% | 1,239.2 8.3% | 2,035.8 64.3% | 2,048.1 0.6% |
| Cost of Goods Sold (COGS) | 0.0 | 42.7 | 61.6 | 73.6 | 89.5 | 100.3 | 119.8 | 144.9 | 167.0 | 188.4 | 195.9 | 220.1 | 230.8 | 263.0 | 283.4 | 308.7 | 400.7 | 430.8 | 977.0 | 1,044.6 |
% margin | 69.4 100.0% | 65.2 60.4% | 162.7 72.5% | 182.7 71.3% | 217.6 70.9% | 248.8 71.3% | 285.6 70.4% | 294.1 67.0% | 326.3 66.1% | 358.8 65.6% | 390.8 66.6% | 410.0 65.1% | 463.8 66.8% | 535.1 67.0% | 574.9 67.0% | 629.2 67.1% | 743.1 65.0% | 808.3 65.2% | 1,058.8 52.0% | 1,003.5 49.0% |
| Operating Expenses | 0.0 | 53.4 | (146.2) | 115.7 | 146.3 | 166.6 | 179.4 | 207.6 | 241.0 | 271.1 | 297.6 | 309.3 | 313.0 | 337.7 | 366.4 | 408.0 | 487.7 | 532.5 | 848.8 | 867.0 |
| Research & Development Expenses (R&D) | 0.0 | 8.5 | 24.9 | 23.0 | 25.5 | 31.7 | 36.0 | 38.4 | 47.1 | 55.6 | 56.6 | 56.6 | 59.4 | 62.0 | 77.0 | 93.3 | 118.7 | 137.2 | 191.4 | 175.2 |
| Selling, General & Administrative Expenses (SG&A) | 0.0 | 43.1 | 91.5 | 91.2 | 120.1 | 134.9 | 143.4 | 169.2 | 193.9 | 215.5 | 241.0 | 252.7 | 253.7 | 275.8 | 289.5 | 314.7 | 369.1 | 395.3 | 657.4 | 664.0 |
% margin | 69.4 100.0% | 16.3 15.2% | 45.8 20.4% | 67.2 26.2% | 71.2 23.2% | 82.3 23.6% | 104.9 25.9% | 86.5 19.7% | 85.2 17.3% | 79.7 14.6% | 103.5 17.6% | 120.3 19.1% | 420.8 60.6% | 197.4 24.7% | 208.0 24.2% | 221.2 23.6% | 255.8 22.4% | 275.8 22.3% | 210.0 10.3% | 136.5 6.7% |
| Interest Income | 0.0 | 0.0 | 0.0 | 0.0 | 2.3 | 0.2 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 13.9 | 5.5 | 0.9 | 1.8 | 3.0 |
| Interest Expense | 0.0 | 9.0 | 0.0 | 0.0 | 0.2 | 0.1 | 0.0 | 0.3 | 1.1 | 17.4 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.3 | 0.3 | 0.4 | 25.7 | 50.3 |
| Pre-tax Income | 0.0 | 7.4 | 314.4 | 68.1 | 72.4 | 82.2 | 107.6 | 86.5 | 83.8 | 75.7 | 102.0 | 116.3 | 418.3 | 199.4 | 213.8 | 234.2 | 263.7 | 274.4 | 193.4 | 88.1 |
% effective tax rate | 73.2 0.0% | (26.0) (353.0%) | 132.6 42.2% | 25.9 38.0% | 40.5 55.9% | 28.2 34.3% | 34.2 31.8% | 22.5 26.0% | 21.9 26.1% | 20.0 26.4% | 27.7 27.1% | 34.8 29.9% | 117.7 28.1% | 67.8 34.0% | 20.2 9.5% | 38.0 16.2% | 23.5 8.9% | 44.7 16.3% | 49.9 25.8% | 6.6 7.5% |
% margin | (3.8) (5.5%) | 33.4 30.9% | 181.8 81.1% | 42.3 16.5% | 31.9 10.4% | 53.2 15.2% | 73.5 18.1% | 63.7 14.5% | 62.3 12.6% | 58.4 10.7% | 72.5 12.4% | 83.3 13.2% | 300.7 43.3% | 131.6 16.5% | 193.5 22.5% | 196.2 20.9% | 240.3 21.0% | 229.6 18.5% | 143.5 7.0% | 81.5 4.0% |
| EPS | (0.41) | 0.57 | 3.79 | 0.71 | 0.57 | 0.92 | 1.25 | 1.07 | 1.08 | 1.03 | 1.33 | 1.62 | 6.28 | 2.42 | 3.45 | 3.67 | 4.39 | 4.16 | 2.68 | 1.54 |
| Diluted EPS | (0.41) | 0.42 | 3.04 | 0.60 | 0.53 | 0.88 | 1.21 | 1.05 | 1.07 | 1.02 | 1.30 | 1.55 | 5.85 | 2.23 | 3.45 | 3.44 | 4.14 | 3.98 | 2.60 | 1.51 |
% margin | 69.4 100.0% | 19.3 17.9% | 49.4 22.0% | 72.5 28.3% | 78.9 25.7% | 88.2 25.3% | 114.2 28.2% | 93.8 21.4% | 94.6 19.2% | 99.1 18.1% | 106.0 18.1% | 134.4 21.3% | (102.4) (14.7%) | 203.8 25.5% | 229.6 26.8% | 259.0 27.6% | 293.8 25.7% | 310.9 25.1% | 355.2 17.4% | 236.7 11.6% |
Discover more Stock Ideas
Undervalued stocks right now
Discover the top 20 best undervalued stocks to buy for Mar 2025, listed on the Nasdaq or NYSE.
3M Return 32.1%
S&P Outperformance 19.1%
Next 3M Predicted Return 20.3%
Undervalued growth stocks
Discover the top 20 best undervalued large-cap growth stocks to buy for Mar 2025, listed on the Nasdaq or NYSE.
3M Return 35.3%
S&P Outperformance 22.3%
Next 3M Predicted Return 26.8%
Undervalued dividend stocks
Discover the top 20 best undervalued high-yield dividend stock that offers both growth potential and attractive dividend returns for Mar 2025.
3M Return 28.4%
S&P Outperformance 15.4%
Next 3M Predicted Return 16.9%
FAQ
1) What is Masimo Corporation's P/EBITDA LTM?
As of today, Microsoft Corp's last 12-month P/EBITDA LTM is 42.1x, based on the financial report for Dec 27, 2024 (Q4’2024). The average annual P/EBITDA LTM for Masimo Corporation have been 32.2x over the past three years, and 37.3x over the past five years.
2) Is Masimo Corporation's P/EBITDA LTM Good?
As of today, Masimo Corporation's P/EBITDA LTM is 42.1x, which is higher than industry median of (0.1x). It indicates that Masimo Corporation's P/EBITDA LTM is Bad.